Iqvia (IQV) announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories (CRL). These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non-animal research methods. The transaction is expected to close in the second quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Iqvia price target lowered to $215 from $266 at Mizuho
- Iqvia price target lowered to $245 from $290 at Truist
- Iqvia price target lowered to $174 from $245 at TD Cowen
- IQVIA: Solid 2026 Outlook but AI Disruption Risks Justify Hold Rating and Lowered Valuation
- Iqvia price target lowered to $240 from $265 at Morgan Stanley